Tryp Therapeutics Strengthens Board of Directors with Appointment of Chris Ntoumenopoulos as Independent Director

Industry leader Chris Ntoumenopoulos to support biotech Company’s mission to advance the delivery of psychedelic medicines SAN DIEGO, May 25, 2022 /PRNewswire/ — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused…

Click here to view original post